Literature DB >> 29119253

Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.

Anna Mania1, Mariusz Kaczmarek2, Paweł Kemnitz3, Katarzyna Mazur-Melewska3, Magdalena Figlerowicz3, Jan Sikora2, Wojciech Służewski3, Jan Żeromski2.   

Abstract

Treatment with pegylated interferon-α and ribavirin (PEG-IFN/RBV) is the only choice for chronic hepatitis C (CHC) in children. Natural killer (NK) cells were described to play a vital role in CHC. The aim of this study was to analyze the expression of peripheral blood NK cell receptors in their relation to PEG-IFN/RBV treatment response. Study included 26 children with CHC-13 boys, age range 13.42 ± 3.28 years. Blood for biochemical, virological and cytometric testing was taken for evaluation prior to the antiviral treatment. NK cell receptors were detected by flow cytometry and the results were presented as proportion of cells and mean fluorescence intensity (MFI). Therapy consisted of PEG-IFNα-2b (60 μg/m2 s.c 1×/week) and RBV (15 mg/kg p.o. daily). Treatment duration was response-related and varied from 12 to 72 weeks. Rapid virological response (RVR) was evaluated in the 4th week and sustained virological response (SVR) 6 months after completion of the therapy. RVR children were younger (11.67 ± 3.74 vs 15.35 ± 2.42; p = 0.001) and displayed higher CD158b (3.58 ± 0.16 vs 3.45 ± 0.13; p = 0.038) and CD158e expression (4.33 ± 0.21 vs 4.03 ± 0.16; p = 0.039). Density of CD158b (logMFI = 3.68 ± 0.22 vs 3.36 ± 0.16; p = 0.036) and CD158e expression was significantly higher (4.37 ± 0.14 vs 4.12 ± 0.21; p = 0.046) and NKG2D expression significantly lower (97.50 ± 3.46 vs 94.92 ± 5.93; p = 0.049) in SVR children. SVR children were also significantly younger (12.40 ± 3.66 vs 15.13 ± 2.83; p = 0.003). Significance of the age of patients, and expression of CD158b and CD158e were confirmed in univariate and multivariate analysis. Age of patients is negatively related to RVR and SVR. NK cell phenotype with higher expression density of CD158b and CD158e receptor was a positive predictor of SVR.

Entities:  

Keywords:  Antiviral treatment; Children; Chronic hepatitis C; NK cell receptors; Pegylated interferon-alpha

Mesh:

Substances:

Year:  2017        PMID: 29119253      PMCID: PMC5780529          DOI: 10.1007/s00430-017-0526-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  25 in total

Review 1.  Natural killer cells in viral hepatitis: facts and controversies.

Authors:  Mario U Mondelli; Stefania Varchetta; Barbara Oliviero
Journal:  Eur J Clin Invest       Date:  2010-06-29       Impact factor: 4.686

2.  Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.

Authors:  Antonio Ascione; Savino Bruno; Carmine Coppola; Alessandra Mangia; Alessandra Orlandini; Manuela Schmitz; Barbara Deodato; Massimo Puoti
Journal:  Hepatogastroenterology       Date:  2014-06

3.  KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.

Authors:  Takeji Umemura; Masao Ota; Yoshihiko Katsuyama; Shuichi Wada; Hiromitsu Mori; Atsushi Maruyama; Soichiro Shibata; Yuichi Nozawa; Takefumi Kimura; Susumu Morita; Satoru Joshita; Michiharu Komatsu; Akihiro Matsumoto; Atsushi Kamijo; Masakazu Kobayashi; Masato Takamatsu; Kaname Yoshizawa; Kendo Kiyosawa; Eiji Tanaka
Journal:  Hum Immunol       Date:  2014-06-11       Impact factor: 2.850

4.  High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Authors:  Stefan Wirth; Carmen Ribes-Koninckx; Maria Angeles Calzado; Flavia Bortolotti; Lucia Zancan; Paloma Jara; Mark Shelton; Nanda Kerkar; Marcela Galoppo; Alejandra Pedreira; Norberto Rodriguez-Baez; Mirta Ciocca; Alain Lachaux; Florence Lacaille; Thomas Lang; Ulrike Kullmer; Wolf Dietrich Huber; Teresita Gonzalez; Henry Pollack; Estella Alonso; Pierre Broue; Jyoti Ramakrishna; Deborah Neigut; Antonio Del Valle-Segarra; Bessie Hunter; Zachery Goodman; Christine R Xu; Hanzhe Zheng; Stephanie Noviello; Vilma Sniukiene; Clifford Brass; Janice K Albrecht
Journal:  J Hepatol       Date:  2010-02-04       Impact factor: 25.083

5.  Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.

Authors:  Lucy Golden-Mason; Christine E Waasdorp Hurtado; Linling Cheng; Hugo R Rosen
Journal:  Clin Immunol       Date:  2015-03-19       Impact factor: 3.969

6.  Human diversity in killer cell inhibitory receptor genes.

Authors:  M Uhrberg; N M Valiante; B P Shum; H G Shilling; K Lienert-Weidenbach; B Corliss; D Tyan; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

7.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

8.  Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.

Authors:  Michelle Spaan; Gertine van Oord; Kim Kreefft; Jun Hou; Bettina E Hansen; Harry L A Janssen; Robert J de Knegt; Andre Boonstra
Journal:  J Infect Dis       Date:  2015-07-28       Impact factor: 5.226

9.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.